Valneva (NASDAQ:VALN) Shares Gap Down – Should You Sell?

Valneva SE Sponsored ADR (NASDAQ:VALN)’s stock price gapped down before the market opened on Monday. The stock had previously closed at $5.71, but opened at $5.35. Valneva shares last traded at $5.3950, with a volume of 176 shares trading hands.

Analysts Set New Price Targets

A number of equities analysts have commented on the company. TD Cowen began coverage on Valneva in a research note on Tuesday, August 11th. They issued a “buy” rating and a $12.00 price target on the stock. Weiss Ratings restated a “sell (e+)” rating on shares of Valneva in a research note on Monday, September 14th. One investment analyst has rated the stock with a Buy rating and two have issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Reduce” and a consensus price target of $9.30.

Valneva Trading Up 3.6%

The company has a debt-to-equity ratio of 2.04, a quick ratio of 1.69 and a current ratio of 2.16. The company has a 50 day simple moving average of $6.13 and a two-hundred day simple moving average of $6.82. The firm has a market cap of $522.84 million, a PE ratio of -2.61 and a beta of 1.37.

Valneva (NASDAQ:VALN) last released its quarterly earnings data on Friday, August 14th. The company reported ($0.40) EPS for the quarter, missing analysts’ consensus estimates of ($0.19) by ($0.21). The business had revenue of $39.37 million during the quarter, compared to analysts’ expectations of $44.17 million. Valneva had a negative net margin of 110.33% and a negative return on equity of 153.20%. Analysts expect that Valneva SE Sponsored ADR will post -1.27 EPS for the current fiscal year.

About Valneva

Valneva SE is a specialty vaccine company focused on developing, manufacturing and commercializing vaccines for infectious diseases with significant unmet medical needs. The company combines vaccine research and development with in-house manufacturing and commercial operations serving public health agencies, travel medicine providers and private healthcare markets.

Valneva’s marketed products include IXIARO and JESPECT for the prevention of Japanese encephalitis, and DUKORAL, an oral vaccine used to help prevent cholera and, in some markets, enterotoxigenic Escherichia coli-related travelers’ diarrhea.